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HIV infection induces the destruction of CD4 lymphocytes, which leads to polyclonal stimulation of B cells and hypergammaglobulinemia, resulting in antibodies against damaged endothelial cells (phospholipids exposed) and inhibition of PS synthesis. [7] [8] [9] The aims of this study were to screen HIV-infected patients for coagulation abnormalities, to detect prothrombotic factors such as deficiency of protein C and S and elevation of homocysteine as possible precursors of coagulation defects in HIV patients and to correlate coagulation abnormalities with CD4 count.
mEtHODs
This was a pilot study of 1-year duration. All diagnosed HIV-seropositive patients (n = 30) who were not taking Vitamin K, antithrombotic and antiplatelet drugs including aspirin, oral contraceptives and not having known protein C/S deficiency were included in the present study as cases. Apart from this, 30 age-and sex-matched healthy individuals were also included in the present study as controls.
Citrated blood sample was collected by venous puncture, both from cases and controls. The collected blood samples (9 parts) were added to one part of 0.11 M trisodium citrate in polystyrene graduated tubes. Ethylenediaminetetraacetic acid blood was collected for complete blood count and platelet morphology.
Assessment of the bleeding time, prothrombin time (PT) and activated partial thromboplastin time (APTT) in all cases and controls was done.
For quality control of PT and APTT, control sample was run daily.
Protein C and S were measured by calorimetric assay. For quality control of protein C and S, calibration curve was made with each lot of reagent opened newly.
Serum homocysteine was measured by the semiautomated method. CD4 count was done by flow cytometry.
The statistical analysis was done using SPSS (Statistical Package for Social Sciences) Version 15.0 Statistical Analysis Software (IBM Headquarters Armonk, New York, US). The values were represented in number (%) and mean ± standard deviation (SD)
The statistical tool employed was mean, median, SD, Chi-Square test, student t-test and level of significance P value.
rEsults
In the present study, it was observed that most of the patients (36.67%) were in the age group between 36 and 45 years, among a total of 30 patients lying in the age group between 20 and 50 years.
Out of 30 patients, 22 (73.33%) were male and 8 (26.77%) were female. About 16 patients had coexistent pulmonary tuberculosis. Table 1 shows the haematological profile in the study population.
In our study, we found that anaemia (P = 0.005) is common in HIV patients as the mean haemoglobin (Hb) of cases was found to be 10.79 ± 1.11 gm/dl as compared to 11.87 ± 1.72 g/dl of controls.
The mean of the platelet count among the HIV-positive patients was low as compared to controls (P < 0.001). It was found that the mean of platelet count for cases was 18.63 ± 5.24 (×10,000)/cu.mm and that of controls was 25.63 ± 6.92 (×10,000)/cu.mm [ Table 1 ].
Mean platelet volume (MPV) among the HIV-positive patients, although in normal range, it was significant low (P < 0.001) in comparison to controls. It was found that the average of MPV of cases was 8.78 ± 1.61fl and that of controls was 10.75 ± 1.26fl.
Low CD4 counts are found in patients with HIV infection, (P < 0.001) as compared to standard reference range, as in the present study, the mean CD4 count of the patients was 405.67 ± 234.50, where the standard is 965 ± 267 (539-1627) (According to IJMR pilot study 2002) [ Table 1 ].
Mean values of protein C activity for cases was 76.31% ± 14.62% and for controls was 110.23 ± 17.07 (P < 0.001); hence, it is imperative that the HIV patients have reduced protein C activity [ Table 2 ]. [10] Mean values of PS activity for cases was 104.87% ± 39.02% and for controls was 109.03% ± 17.07% (P = 0.594). Hyperhomocysteinaemia (HHcy) was found in 24 (80%) out of 30 patients (P < 0.001) compared to controls with normal homocysteine. The mean value of homocysteine in patients is 23.63 ± 9.16 µmol/L and in controls is 9.23 ± 3.26 µmol/L; therefore, the levels of homocysteine are higher in HIV patients.
APTT was raised in 15 (50%) out of 30 patients as the mean value was 47.33 ± 16.54 s for cases (P < 0.001) and 33.73 ± 3.97 s for controls.
Out of 30 patients, 15 had raised APTT, but only one developed mucosal bleeding in the form of epistaxis.
PT was raised in 11 (36.8%) out of 30 patients, and the mean value of PT for cases was 19.63 ± 10.31 s and for controls was 13 ± 1.95 s. Hence, it is inferred that PT is raised in HIV patients as compared to controls (P < 0.001) [ Table 2 ].
There was no significant difference found between bleeding time of cases and controls.
In our study, there was no correlation found between Hb levels and CD4 counts. However, platelet counts are related with CD4 counts. The patients with CD4 counts <200/µL have mean of platelet count 14 ± 2.68 (×10,000) cu.mm as compared to the patients with CD4 counts between 200 and 500/µL in whom mean of platelet count was 18.47 ± 4.29 (×10,000)/cu.mm, and in the patients with CD4 count >500/µL, the mean of platelet count was 22.11 ± 5.69 (×10,000)/cu.mm. Thus, a decrease in CD4 count levels has been associated with a decrease in mean platelet count [ Table 3 ].
The MPV was related with CD4 counts. Our study reveals that the average of MPV is lower in CD4 counts <200/µL as compared to higher CD4 counts.
In patients with CD4 counts <200/µL, the mean value of protein C activity was 66.40% ± 14.16% as compared to CD4 count between 200 and 500/µL in whom the mean value was (%) 74.51 ± 8.31/µL, and in patients with CD4 count >500/µL, the mean of protein C activity was (%) 85.91 ± 18.58 [ Table 3 ].
Thus, the decrease in protein C activity levels is associated with decreasing CD4 count levels.
In patients with CD4 counts <200/µL, the mean value of PS activity 55.67% ± 8.71% as compared to CD4 count between 200 and 500/µL in whom mean value was (%) 107.07 ± 38.30, and in patients with CD4 count >500/µL, the mean of PS activity was (%) 134 ± 11.24. Thus, in our study, the level of PS activity is correlated with CD4 counts.
Patients with CD4 counts <200/µl have mean value of homocysteine 35 ± 4.60 µmol/L as compared to the patients with CD4 count between 200 and 500/µl in whom the mean values of homocysteine was 23.07 ± 7.99 µmol/L and in patients CD4 count >500/µl, the mean value was 17 ± 5.68 µmol/L. Thus, patients with CD4 count between 200 and 500/µl have a higher mean value of homocysteine than patients with CD4 counts >500/µl [ Table 3 ].
APTT and PT both are raised in HIV patients as compared to controls, and the difference between the values is found significant.
In the present study, we found that patients with CD4 counts <200/µl have mean value of PT 24. 17 Table 3 ].
We found that out of 30, only two patients (6.67%) developed thromboembolism. These patients presented with myocardial infarction and stroke. The mean CD4 counts of patients with thromboembolism were 71.50 ± 41.72/µl whereas non-embolic patients were having 429.54 ± 223.92/µl [ Table 4 ]. 
DiscussiOn
HIV infection may result in variable haematologic manifestations. Several clinical studies have reported a higher risk of thrombotic complications among HIV-infected patients. The risk of venous thrombotic events has been described 6.5-10 times, more prevalent in these patients than in general population. [11] In the present study, mean Hb of cases was 10.79 gm/dl as compared to 11.87 gm/dl of controls [ Table 1 ]. Anaemia is a frequent complication of HIV infection. Ramezani et al. observed that mild-to-moderate anaemia existed in 46% of 143 HIV-infected patients. However, Abdollahi and Shoar observed no significant difference in Hb levels between patients and controls (P = 0.769). This finding may be attributable to the number of participants included or the supplementary treatment with iron or folate-vitamin B12 complex. However, they found that there is a moderately strong positive correlation between the Hb levels and CD4 count. Whereas, in the present study, there was no relation found between Hb levels and CD4 counts [ Table 3 ]. [11, 12] The present study showed a significant reduction in CD4 count in HIV-seropositive patients compared with their seronegative counterparts (P < 0.001). The HIV attacks and destroys cells with the CD4 antigen, and this explains why HIV-positive patients had lower CD4 counts than HIV-negative individuals. [13] Abdollahi and Shoar concluded that the HIV-infected patients, compared to healthy controls, showed a significant decline in platelets, CD4 count (P < 0.0001) and an increase of homocysteine (P < 0.0001). No statistical difference was found between patients with CD4 count ≤200/µL and CD4 count >200/µL in the evaluated variables. [11] In the present study, platelet count of patients is low as compared to controls [ Table 1 ], and there was no significant difference between the platelet count in patients with high and low CD4 counts [ Table 3 ]. However, in the study of Omoregie et al., there was no significant difference (P > 0.05) in the platelet count of HIV-positive patients whose CD4 count were <200/µL and those with CD4 count ≥200/µL. It has been reported that patients with AIDS have decreased platelet production whereas patients with early-onset HIV infection are more likely to have increased peripheral destruction of platelet by antiplatelet antibodies. [13, 14] Impaired thrombopoiesis can result from infection of megakaryocytes by HIV because megakaryocytes possess CD4 and CXCR4, which are known receptors for HIV, and various megakaryocyte lines are infectable with HIV. [13, 14] Human megakaryocytes have a CD4 molecule capable of binding HIV. Thrombocytopenia is a frequent complication of HIV-1 infection and appears to result from a combination of decreased platelet and impaired platelet production. The platelet count generally improves promptly after reticuloendothelial cell suppression or ablation, suggesting an immunologic aetiology or within 1 week after anti-HIV-1 treatment with azidothymidine (AZT), suggesting megakaryocyte suppression, possibly due to the invasion of megakaryocytes with HIV-1. The evidence that megakaryocyte can be directly infected by HIV-I is supported by morphologic abnormalities of megakaryocytes, the detection of HIV-1 viral mRNA in some megakaryocytes of HIV-seropositive individuals, the susceptibility of megakaryocyte cell lines in culture to productive infection with HIV-1, decreased megakaryocyte precursors and improvement of impaired platelet turnover after treatment with AZT. [14] In the present study, the values of PT and APTT in HIV patients were significantly higher than the values in HIV-negative individuals (P < 0.001). In the study of Omoregie et al., the PT (P < 0.005) and APTT (P < 0.001) of HIV-positive patients with CD4 count < 200 cells/µL were significantly higher than those of HIV patients with CD4 count ≥200 cells/µL. The possible explanation is that as the HIV infection progress, which is characterised by reduction in CD4 count, endothelial activation and possibly liver damage may increase resulting in the consumption of blood clotting factors and/or abnormal production of liver-dependent clotting factors, resulting in increased PT and APTT. [13] Tissue factor (TF) released by subendothelial cells during vascular damage, binds to circulating factor VII with the formation of VIIa. The TF: VIIa complex activates X to Xa and this proceeds through the usual coagulation cascade. This indicates that endothelial activation is mainly responsible for the increased PT and APTT observed in this study. Factor VII assay and the effect of CD4 count on factor VII concentration may confirm this. It also seems likely that PT could be used as a means of HIV disease progression in resource-poor settings where CD4 count is impossible, just as anaemia is used as a marker of disease progression. At this cut-off value of CD4 count (<200 cells/µL), the corresponding PT of >21 s may indicate lower immunity, the possible appearance of opportunistic infections. [13] In conclusion, PT and APTT are higher in HIV patients with CD4 count <200 cells/µL. Endothelial activation is suggested as the cause of the coagulation defect. HIV infection is associated with endothelial damage, which can result in the activation and consumption of blood clotting factors. In addition, lupus anticoagulant, anticardiolipin antibodies and liver damage are seen in HIV-infected patients. All these can affect PT and APTT and may explain the high PT and APTT values observed among HIV patients. [13, 15] Fultz et al. found that among the HIV-infected patients, platelet count did not differ significantly (P > 0.05) between those with CD4 count <200 cells/µL and those with CD4 count ≥200 cells/µL. However, PT and APTT were significantly (P < 0.005 and P < 0.001, respectively) higher in HIV patients with CD4 count <200 cell/µ. [16] In our study, the MPV is low in cases as compared to controls and the difference is significant [ Table 1 ]. MPV also have a relationship with CD4 counts, the average of MPV is lower in CD4 counts <200/µL as compared with higher CD4 counts [ Table 3 ]. Whereas, other studies show that MPV is a marker of atherothrombosis in HIV-infected treatment-naive patients; and MPV increases significantly during the untreated asymptomatic HIV infection. Mena et al. concluded that platelet activation and aggregation are central processes in the pathophysiology of atherosclerosis. MPV is a simple and accurate way to estimate platelet activity. Larger platelets are more active, contain more prothrombotic agents and are more likely to aggregate. Recently, in general population, MPV has been shown as an independent risk factor for myocardial infarction and peripheral artery disease. We have found a larger MPV, a marker of atherothrombosis, in HIV-infected treatment-naive patients and MPV increases significantly during the untreated asymptomatic HIV infection. [17] In our study, mean values of protein C and S activity are low in patients as compared to controls [ Table 2 ], and there is a correlation between CD4 count levels and decrease in protein C and S activity [ Table 3 ]. Decrease in protein C and S activity are a cause of increased thrombosis. It is currently accepted that PS deficiency is a significant contributor to the procoagulant nature of HIV infection. In a study by Bibas et al., PS deficiency is the most consistently observed coagulation abnormality observed in HIV-infected patients, with a reported prevalence ranging from 27% to 76%, with 12% of those patients having a venous thromboembolism. [18] The mechanism of protein C deficiency in HIV-infected persons is multifactorial, including altered synthesis and metabolism as well as low-grade DIC with consumptive coagulopathy. [18] In the present study, HHcy was found in 24 (80%) out of 30 patients, and the levels of homocysteine are significantly higher in HIV patients as compared to controls.
A raised homocysteine level is a risk factor of thrombosis. Mild-to-moderate HHcy is relatively common in HIV-infected individuals, especially those using cART, with a prevalence ranging from 11% to 29%. [19] In our study, 53.33% of cases were affected with tuberculosis as compared to 13.33% of controls. Mycobacterium avium-intracellulare and Mycobacterium tuberculosis may induce anticardiolipin antibodies and a hypercoagulable state. Declining levels of anticardiolipin antibodies seem to occur after the initiation of effective treatment of underlying infection. It can activate macrophages directly and induces them to produce cytokines, especially TNF-α, interleukin (IL)-1 and IL-6. TNF-α and IL-1 block the protein C anticoagulant pathway and can elicit TF production on endothelium and monocytes. IL-6 can also stimulate new platelets formation which has increased sensitivity to thrombin activation and increased procoagulant activity. [18] We found that out of 30, only two patients (6.67%) developed thromboembolism in the form of myocardial infarction and stroke. The mean CD4 counts of patients with thromboembolism were 71.50 ± 41.72/µL, whereas non-embolic patients were having 429.54 ± 223.92/µL. Zimba et al. did a similar kind of study in Zambia in HIV cases. They concluded that HIV-positive adults with ischaemic strokes have more PS deficiency and HHcy as compared to HIV-negative adults with ischaemic stroke. [20] cOnclusiOn The findings of the present study suggest a relationship between HIV, its complications and thrombosis. The HIV-seropositive patients have reduced the levels of Hb, CD4 counts, platelet counts, MPV, protein C and S activity as compared to the healthy controls. Platelet count, MPV, protein C and S activity are correlated with CD4 counts.
HIV patients have higher PT and APTT values as compared to controls; APTT and PT are correlated with CD4 count, and endothelial activation is suggested as the possible mechanism for the coagulation defect.
The results showed that thrombophilic abnormalities are frequent in HIV-infected patients and physicians should be aware of this fact to prevent thrombotic complications in HIV patients.
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